Table 3.

Comparison between the TPE (−) and TPE (+) groups.

	TPE (−) (n = 247)	TPE (+) (n = 75)
	Mean ± SD (median)	Mean ± SD (median)
Age (months)	114.33 ± 52.32	136.27 ± 55.52	0.001*
PICU duration	5 (3–8)	7 (5–12)	0.002*
PRISM III score	9 (6–16)	15 (8–28)	<0.001*
PELOD score	10 (5–11)	15 (11–29)	0.002*
Number of organ system disease	4 (3–5)	4 (3–6)	a0.001*
VIS	15 (10–25)	20 (12–55)	0.001*
Presence of shock	156 (63.2%)	59 (78.7%)	b0.013*
Severe cardiac impairment EF <30%	7 (2.8%)	9 (12%)	c0.004*
Mechanical ventilation	24 (9.7%)	31 (41.3%)	b<0.001*
Immunomodulatory treatment—anakinra	42 (17%)	30 (40%)	b<0.001*
Immunomodulatory treatment—tocilizumab	4 (1.6%)	7 (9.3%)	c0.004*

TPE therapeutic plasma exchange, PRISM pediatric risk of mortality, PELOD pediatric logistic organ dysfunction, VIS vasoactive inotropic score, EF ejection fraction.

*p < 0.05.

^aMann–Whitney U-test; shown in the table as the median (Q1–Q3).

^bPearson chi-square test.

^cFisher’s exact test.